Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis ... has confirmed that Kite's R&D as well as its commercial operations will remain based in ...

Gilead's commercial success underscores the dedication ... a first-in-class capsid inhibitor that was recently recognized by science as 2024's breakthrough of the year. To put this in context ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration approval, with a decision expected in mid-June, Gilead Sciences Inc. announced ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full ... Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Dietmar Berger; and our ...